ARTICLE | Company News
AstraZeneca, Rigel in asthma deal
June 20, 2012 12:47 AM UTC
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive, worldwide rights to develop and commercialize inhaled Janus kinase (JAK) inhibitor R256. The compound is...